Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | inhibitor of apoptosis protein | 0.0041 | 0.3658 | 0.3658 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0057 | 1 | 0.5 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0057 | 1 | 0.5 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0057 | 1 | 0.5 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.0057 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.3658 | 0.3658 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0057 | 1 | 0.5 |
Onchocerca volvulus | 0.0041 | 0.3658 | 0.5 | |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.0057 | 1 | 1 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0057 | 1 | 0.5 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0057 | 1 | 1 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0057 | 1 | 0.5 |
Mycobacterium ulcerans | proteasome PrcB | 0.0057 | 1 | 0.5 |
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.0057 | 1 | 0.5 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0057 | 1 | 0.5 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0057 | 1 | 1 |
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0057 | 1 | 0.5 |
Onchocerca volvulus | Deterin homolog | 0.0041 | 0.3658 | 0.5 |
Schistosoma mansoni | inhibitor of apoptosis (iap) domain family member | 0.0041 | 0.3658 | 0.3658 |
Echinococcus granulosus | proteasome prosome macropain | 0.0057 | 1 | 1 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0057 | 1 | 0.5 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0057 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.